Alteogen has entered into an exclusive license agreement with Daiichi Sankyo for the development and commercialisation of a subcutaneous version of ENHERTU (fam-trastuzumab deruxtecan-nxki), an antibody drug conjugate (ADC).
Plus Therapeutics has entered into a manufacturing services agreement (MSA) with SpectronRx to produce the radiotherapy, Rhenium (186Re) Obisbemeda, for central nervous system (CNS) cancers.
Ring Therapeutics has entered into new strategic partnerships with the Agency for Science, Technology, and Research (A*STAR) and the Singapore Eye Research Institute (SERI) to enhance research and development (R&D) efforts in the biomedical sciences sector.
NEOGAP Therapeutics has entered into a partnership with NorthX Biologics, a Swedish contract development and manufacturing organisation (CDMO), to enhance the manufacturing strategies for its personalised cancer cell therapy.
The US Food and Drug Administration (FDA) has granted expanded approval to Shorla Oncology’s JYLAMVO (methotrexate) for use in paediatric indications.
Kivu Bioscience has completed a $92m Series A funding round, spearheaded by Novo Holdings to propel the development of next-generation antibody-drug conjugates (ADCs).
The US Food and Drug Administration (FDA) has granted clearance for RiboX Therapeutics’ investigational new drug (IND) application to commence a Phase I/IIa clinical trial of RXRG001, circular RNA therapy.
Lyell Immunopharma has entered into a definitive agreement for the acquisition of ImmPACT Bio USA, a move that is expected to prioritise its pipeline to focus on chimeric antigen receptor (CAR) T-cell therapies.
MacroGenics has granted global rights to the breast cancer drug MARGENZA (margetuximab) to TerSera Therapeutics.
Novartis has received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP), recommending marketing authorisation for Kisqali (ribociclib) as an adjuvant treatment for certain early breast cancer patients.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.